摘要
目的探讨局部晚期NSCLC患者采用紫杉醇联合顺铂同步放化疗的临床效果。方法回顾性分析2012年1月～2014年6月在我院治疗的40例局部晚期NSCLC患者临床资料,按照随机数字表法分为两组,对照组18例予以放疗治疗,研究组22例给予紫杉醇联合顺铂同步放化疗。比较两组患者临床疗效、不良反应情况、治疗后kamofsky评分(KPS)、患者生活质量评分(QOL)以及1、3年生存情况。结果研究组客观有效率(50.00%)显著高于对照组(16.66%),差异有统计学意义(P <0.05)。研究组疾病控制率(77.27%)显著高于对照组(44.44%),差异有统计学意义(P <0.05)。研究组不良反应发生率显著高于对照组,差异有统计学意义(P <0.05)。研究组KPS评分及QOL评分改善率显著优于对照组,差异有统计学意义(P <0.05)。两组中位生存时间及1、3年生存率比较有显著差异,差异有统计学意义(P <0.05)。结论紫杉醇联合顺铂同步放化疗可提高临床疗效,延长生存时间,改善生活质量,但不良反应率较高,但毒副反应可以耐受,也可以作为一个治疗方案应用于临床。
Objective To explore the clinical effect of paelitaxel combine with eisplatin synchronous ehemoradiotherapy in locally advanced NSCLC. Methods Fourty patients with locally advanced NSCLC in PuNing Overseas Chinese Hospital from January 2012 to June 2014 were selected,and their data were retrospectively analyzed,they were divided into 2 groups according to random number method,18 eases in the control group were treated by radiotherapy,22 eases in the study group were treated by paelitaxel and eisplatin synchronous ehemoradiotherapy.The clinical efficacy, adverse reactions,post- treatment kamofsky score （KPS）,patient quality of life score （QOL）,and 1 and 3 year survival were compared between the two groups. Results The objective efficiency of the study group （50.00%） was significantly higher than that of the control group （16.66%）.The disease control rate of the study group （77.27%） was significantly higher than that of the control group （44.44%） （1- 〈 0.05）.The incidence of adverse reactions in the study group was significantly higher than that in the control group （1- 〈 0.05）.The improvement rate of KPS score and QOL score of the study group was significantly better than that of the control group（P 〈 0.05）.There was a significant difference in median survival time and 1 and 3 year survival rates between the two groups （P 〈 0.05）. Conclusion Paelitaxel combine with eisplatin synchronous ehemoradiotherapy can improve clinical efficacy,prolong survival time and improve quality of life,however,the adverse reaction rate is high,but the toxic side reaction can be tolerated.h can also be used as a treatment program for clinical application.
作者
方海城
陈钢群
韦慎彬
潘旭彬
FANG Haicheng;CHEN Gangqun;WEI Shenbin;PAN Xubin(Radiotherapy Center,Puning Overseas Chinese Hospital,GuangDong Province,PuNing 515300,China)
出处
《中国医药科学》
2018年第19期251-254,共4页
China Medicine And Pharmacy
关键词
局部晚期NSCLC
紫杉醇
顺铂
同步放化疗
Locally advanced NSCLC
Paelitaxel
Cisplatin
Synehronous ehemoradiotherapy
